Varsity Healthcare Partners Invests in Trialbee to Accelerate Clinical Trial Patient Recruitment
Key Insights
Varsity Healthcare Partners (search) completed a strategic growth investment in Trialbee (search), a Sweden-based technology-enabled provider of patient recruitment services for clinical trials.
Trialbee (search) addresses the critical challenge of timely patient enrollment through its proprietary Honey platform, which centralizes recruitment activities and provides real-time tracking and ROI reporting.
The investment will support Trialbee (search)'s expansion in commercial scale, technology innovation, and global delivery capabilities to help biopharma sponsors accelerate therapy development.
Varsity Healthcare Partners (search) (VHP), a lower middle-market healthcare services private equity firm, has completed a strategic growth investment in Trialbee (search), a Sweden-headquartered technology-enabled provider of patient recruitment services and analytics for clinical trials. The investment aims to address one of the most significant challenges in clinical development – timely and effective patient enrollment.
Technology-Driven Patient Recruitment Platform
Trialbee (search) works with global biopharma sponsors to help them meet enrollment timelines and patient diversity goals by combining data-driven targeting with omnichannel marketing and advertising across regions, channels, and patient populations. The company's recruitment efforts are supported by its proprietary Honey platform, which Trialbee describes as a vendor-agnostic SaaS system that centralizes recruitment activities from interest through enrollment.
The Honey Platform provides unprecedented transparency and actionable insights for real-time patient tracking, higher-quality referrals that reduce site burden, and robust ROI reporting. The platform centralizes and standardizes all recruitment activities from every source, channel, and partner, offering comprehensive oversight of the patient recruitment process.
Strategic Partnership for Growth
VHP will partner with Trialbee (search)'s management team to support continued growth, including investments in commercial scale, technology innovation, and global delivery capabilities. Trialbee CEO Matt Walz will continue to lead the company with the existing senior leadership team.
"Trialbee (search) has built a differentiated, technology-enabled platform that addresses a mission-critical need for biopharma sponsors, while building trust with both research sites and patients," said Walz. "Varsity, which brings deep healthcare services expertise and a proven track record of scaling founder- and management-led platforms, is an ideal partner for us during this next chapter as we continue to invest in our technology, expand our capabilities, and help more sponsors accelerate the development of life-changing therapies."
Comprehensive Recruitment Solutions
Trialbee (search) serves as a single, accountable partner for patient recruitment, combining technology and high-touch execution to help sponsors reach hard-to-access patient populations, speed up trial enrollment timelines, and improve overall trial outcomes. The company's approach includes data-driven modeling based on consumer behavior and other real-world data, hyper-targeted digital outreach, thoughtfully designed site and patient materials, two-step pre-qualification, and meaningful omnichannel partners focused on meeting patients where they are in the treatment journey.
The Honey platform is surrounded by a team of global recruitment experts who meet patients where they are in their journey, providing comprehensive support throughout the recruitment process. This integrated approach aims to revolutionize the patient recruitment ecosystem through technology, people, and strategic partnerships.
Piper Sandler (search) served as the financial advisor to VHP on the transaction, though financial terms were not disclosed. The investment reflects the growing importance of technology-enabled solutions in addressing clinical trial recruitment challenges faced by the biopharmaceutical industry.